"Colossal is thrilled to welcome ViaGen, the world's leading cloning company, into our portfolio. No other company comes close to what ViaGen has achieved. Their unmatched expertise and cloning technology stack have become the world's standard and their application of these critical and proprietary technologies to endangered species conservation makes them an invaluable partner in advancing our global de-extinction and species preservation mission."
"Earlier this year, the company claimed to have "brought back" dire wolves, an assertion that was disputed by some experts, as the animals were created by modifying the DNA of existing gray wolves. The company has also sparked debates about the ethics of bringing species back from extinction, or if what it's doing is in fact "de-extinction" at all."
Colossal Biosciences, founded in 2021, acquired ViaGen Pets and Equine, marking its first acquisition. ViaGen, founded in 2002, will remain under existing leadership and expand endangered species cloning work. Colossal has pursued de-extinction projects and claimed to have recreated dire wolves by modifying gray wolf DNA, a claim met with expert dispute and ethical debate. Colossal recently raised $120 million to attempt dodo resurrection. ViaGen brings industry-leading cloning capabilities and exclusive licensing to Roslin Institute breakthroughs, including techniques linked to cloning Dolly the sheep. Terms of the acquisition were not disclosed.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]